# CYTOSHRINK (NCT04090710)

> SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04090710
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Ontario Clinical Oncology Group (OCOG)
- Conditions: Metastatic Renal Cell Carcinoma
- Interventions: Ipilimumab/ Nivolumab; SBRT + Ipilimumab/Nivolumab
- Enrollment: 66
- Primary outcome: Progression free survival (PFS)

## Commentary we found

- X threads: 21
- YouTube: 5
- Podcasts: 5
- X videos: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=cytoshrink-nct04090710

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04090710", "email": "<work email>"}; the inbox owner confirms by the emailed link.